The Benefits of Neuroids /Neuropeptides in Combating , Neurological, and Ocular Diseases.

α
Ishaq Khan
Ishaq Khan

Send Message

To: Author

The Benefits of Neuroids /Neuropeptides in Combating , Neurological, and Ocular Diseases.

Article Fingerprint

ReserarchID

045L1

The Benefits of Neuroids /Neuropeptides in Combating , Neurological, and Ocular Diseases. Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

Neuroids and neuropeptides (ND/NPs) are drugs with promising efficacy in cerebrovascular diseases. In this article the benefits and mechanisms of action of ND/NPs for stroke are reviewed in light of the pathogenesis of stroke. The primary mechanism is that ND/NPs help in the synthesis of acetylcholine and betaine. These, in turn, work to help in the formation of nerve cell membrane phospholipids and attenuate the production of free radicals. This is important in stroke because brain damage after stroke is associated with excess production of free radicals. Furthermore, ND/NPs may stimulate the activity of glutathione reductase and have the ability to promote learning and improve cognitive impairment. Pharmacokinetics suggests that ND/NPs are well absorbed, with a higher degree of bioavailability when administered orally. A dose of 500 mg to 2,000 mg per day in slow releasing form is an effective regimen based on clinical trials, and is safe for use in elderly population and pediatrics.

References

26 Cites in Article
  1. Susan Margulies,Gail Anderson,Fahim Atif,Jerome Badaut,Robert Clark,Philip Empey,Maria Guseva,Michael Hoane,Jimmy Huh,Jim Pauly,Ramesh Raghupathi,Stephen Scheff,Donald Stein,Huiling Tang,Mona Hicks (2016). Combination Therapies for Traumatic Brain Injury: Retrospective Considerations.
  2. Junko Morita,Kuniyuki Kano,Kazuki Kato,Hiroyuki Takita,Hideki Sakagami,Yasuo Yamamoto,Emiko Mihara,Hirofumi Ueda,Takanao Sato,Hidetoshi Tokuyama,Hiroyuki Arai,Hiroaki Asou,Junichi Takagi,Ryuichiro Ishitani,Hiroshi Nishimasu,Osamu Nureki,Junken Aoki (2016). Structure and biological function of ENPP6, a choline-specific glycerophosphodiester-phosphodiesterase.
  3. Samo Ribarič (2016). The Rationale for Insulin Therapy in Alzheimer’s Disease.
  4. C Edward,Jauchec (2017). Ischemic Stroke Clinical Presentation.
  5. Maria Luca,Antonina Luca,Carmela Calandra (2015). The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer’s Disease and Vascular Dementia.
  6. D Liebeskind,O' Connorre (2017). Hemorrhagic Stroke Clinical Presentation.
  7. Seyedhossein Ojaghihaghighi,Samad Vahdati,Akram Mikaeilpour,Ali Ramouz (2017). Comparison of neurological clinical manifestation in patients with hemorrhagic and ischemic stroke.
  8. Silvia Vincenzetti,Valeria Polzonetti,Daniela Micozzi,Stefania Pucciarelli (2016). Enzymology of Pyrimidine Metabolism and Neurodegeneration.
  9. Mallikarjunarao Ganesana,Scott Lee,Ying Wang,B Venton (2016). Analytical Techniques in Neuroscience: Recent Advances in Imaging, Separation, and Electrochemical Methods.
  10. Gelu Onose,Cristina Daia,Monica Haras,Tiberiu Spircu,Aurelian Anghelescu,Ciurea,Anca Mihaescu,Liliana Onose (2011). A long-term, complex, unitary appraisal regarding neurorestorative, including neurorehabilitative, outcomes in patients treated with Cerebrolysin®, following traumatic brain injury.
  11. Bin-Yin Li,Ying Wang,Hui-Dong Tang,Sheng-Di Chen (2017). The role of cognitive activity in cognition protection: from Bedside to Bench.
  12. Edward Walter,Mike Carraretto (2016). The neurological and cognitive consequences of hyperthermia.
  13. Pawel Grieb,Anselm Jünemann,Marek Rekas,Robert Rejdak (2016). Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma.
  14. Khanh Bui,Fahua She,Michael Hutchison,Åsa Brunnström,Mark Sostek (2015). Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects.
  15. Kewal Jain (2011). Neuroprotective Agents.
  16. Zeltzin Ceja-Galicia,Alberto Daniel,Ana Salazar,Pablo Pánico,Patricia Ostrosky-Wegman,Andrea Díaz-Villaseñor (2017). Effects of arsenic on adipocyte metabolism: Is arsenic an obesogen?.
  17. Henry Querfurth,Frank Laferla (2010). Alzheimer's Disease.
  18. M Prins,T Greco,D Alexander,C Giza (2013). The pathophysiology of traumatic brain injury at a glance.
  19. Patricia Tagliaferro,Robert Burke (2016). Retrograde Axonal Degeneration in Parkinson Disease.
  20. Deepdiveadmin (2015). LAS VEGAS SANDS CORP., a Nevada corporation, Plaintiff, v. UKNOWN REGISTRANTS OF www.wn0000.com, www.wn1111.com, www.wn2222.com, www.wn3333.com, www.wn4444.com, www.wn5555.com, www.wn6666.com, www.wn7777.com, www.wn8888.com, www.wn9999.com, www.112211.com, www.4456888.com, www.4489888.com, www.001148.com, and www.2289888.com, Defendants..
  21. K Bonsu,I Owusu,K Buabeng,D Reidpath,A Kadirvelu (2016). Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.
  22. Isin Kulaksizoglu (2007). Mood and Anxiety Disorders in Patients with Myasthenia Gravis.
  23. N Volkow,G-J Wang,J Logan,D Alexoff,J Fowler,P Thanos,C Wong,V Casado,S Ferre,D Tomasi (2015). Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain.
  24. H Danesh-Meyer,L Levin (2015). Glaucoma as a neurodegenerative disease.
  25. Jagat Kanwar,Sriramoju,Kanwar (2012). Neurological disorders and therapeutics targeted to surmount the blood–brain barrier.
  26. P Lapchak,J Zhang (2017). Neuroprotective Therapy for Stroke and Ischemic Disease.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Ishaq Khan. 2017. \u201cThe Benefits of Neuroids /Neuropeptides in Combating , Neurological, and Ocular Diseases.\u201d. Global Journal of Medical Research - A: Neurology & Nervous System GJMR-A Volume 17 (GJMR Volume 17 Issue A1): .

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-A Classification: NLMC Code: WL 358.5, WL 302, WW 410
Version of record

v1.2

Issue date

November 22, 2017

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 3470
Total Downloads: 1587
2026 Trends
Related Research

Published Article

Neuroids and neuropeptides (ND/NPs) are drugs with promising efficacy in cerebrovascular diseases. In this article the benefits and mechanisms of action of ND/NPs for stroke are reviewed in light of the pathogenesis of stroke. The primary mechanism is that ND/NPs help in the synthesis of acetylcholine and betaine. These, in turn, work to help in the formation of nerve cell membrane phospholipids and attenuate the production of free radicals. This is important in stroke because brain damage after stroke is associated with excess production of free radicals. Furthermore, ND/NPs may stimulate the activity of glutathione reductase and have the ability to promote learning and improve cognitive impairment. Pharmacokinetics suggests that ND/NPs are well absorbed, with a higher degree of bioavailability when administered orally. A dose of 500 mg to 2,000 mg per day in slow releasing form is an effective regimen based on clinical trials, and is safe for use in elderly population and pediatrics.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

The Benefits of Neuroids /Neuropeptides in Combating , Neurological, and Ocular Diseases.

Ishaq Khan
Ishaq Khan

Research Journals